Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses

Akarsu, Sevgi; Aktan, Şebnem; Atahan, A.; Koç, Pınar; Özkan, Şebnem

doi:10.1111/j.1365-2230.2010.03999.x

Cited by 30 publications

(28 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IMQ is a toll-like receptor agonist, which is used to treat condyloma acuminata, solar keratosis, basal cell carcinoma and other conditions [27, 28]. Van der Fits et al revealed that IMQ-induced psoriasis-like inflammation markedly reflected the characteristics of plaque type psoriasis, which include hyperproliferative keratinocyte, parakeratosis, absence of a granular layer, and existence of inflammatory cells consisting of T cells, neutrophils, DCs and vascular proliferation [23].…”

Section: Discussionmentioning

confidence: 99%

Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice

Zhang

Liu

Mei

et al. 2016

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundPsoriasis is a chronic inflammatory immune disease with undefined pathogenesis. It is associated with T cells, and the IL-23/IL17 axis is believed to be crucial in the pathogenesis. The present treatments have side effects that influence the compliance of patients. Tea polyphenol is extracted from tea polyphenols, and its main active ingredient is Epigallocatechin-3-gallate (EGCG), which has been shown to have antioxidant, anti-tumor, and anti-ultraviolet radiation effects. Here, we aim to report that EGCG can inhibit imiquimod (IMQ)-induced psoriasis-like inflammation.MethodsWe used BALB/c mice, which were topically treated with IMQ for 6 consecutive days, as a psoriasis mouse model. Topical application of EGCG and treatment with EGCG were conducted in the experiments. Then observed the effects of the two methods on psoriasis-like mice dermatitis. Statistics are presented as the means ± standard error of mean (SEM) and compared using unpaired two-tailed Student’s t tests or one-way ANOVA.ResultsTopical application of EGCG alleviated psoriasiform dermatitis, improved the skin pathological structure by reduce the expression of epidermal PCNA, promoted the expression of caspase-14. Treatment with EGCG attenuated skin inflammation, accompanied by reduced infiltrations of T cells; reduced percentages of CD11c+ DC in the composition of immunocytes of spleens; reduced levels of interleukin (IL)-17A, IL-17F, IL-22, IL-23 and malondialdehyde (MDA) in plasma; increased percentages of CD4+ T cells in the composition of immunocytes of spleens; and increased bioactivities of superoxide dismutase (SOD) and catalase (CAT) in plasma.ConclusionsAll the results demonstrated that EGCG had anti-inflammatory, immune regulatory and antioxidant effects. It is a promising intervention in psoriasis in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice

Zhang

Liu

Mei

et al. 2016

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…Indeed, topical therapy has been proposed to reduce the potential gastrointestinal and cardiovascular side effects of conventional NSAIDs in the treatment of actinic keratosis (21), pain (22) and arthritis (23). The topical administration of P-S to mice bearing human skin cancer xenografts resulted in 4- to 5-fold lower levels of sulindac and its metabolites (<35 μM) compared to those after oral administration (>200 μM) (12).…”

Section: Discussionmentioning

confidence: 99%

Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer

Cheng

Mattheolabakis

Wong

et al. 2012

International Journal of Oncology

View full text Add to dashboard Cite

Phospho-sulindac (P-S, OXT-328), a novel sulindac derivative, has shown superior anticancer efficacy and safety compared to sulindac. In this study, we investigated the efficacy of topical P-S hydrogel in the treatment of non-melanoma skin cancer in preclinical models. P-S is a potent inhibitor of A431 epidermoid carcinoma in vitro and achieves this effect by inhibiting cell proliferation and inducing apoptosis. The anticancer efficacy of topical and oral P-S was further evaluated in mice bearing A431 intradermal xenografts. Compared to the controls, topical P-S hydrogel inhibited the A431 xenografts by 70.5% (p<0.01), while oral P-S inhibited it by 43.4% (p<0.05), being significantly less effective than topical P-S (p= 0.017). Topical P-S hydrogel generated significant levels (>500 nmol/g tumor tissue) of intact P-S in the tumors, accounting for 92.5% of the total metabolites in the A431 xenografts. This local delivery of high levels of intact P-S to the A431 xenografts is an important contributor to the potent activity of topical P-S and no local or systemic side effects were noted in the treatment group. Thus, topical P-S is a promising treatment modality against non-melanoma skin cancer and merits further evaluation.

show abstract

“…conducted a study comparing the use of 3% diclofenac sodium and 5% imiquimod and found similar cure rates at the end of treatment in both groups, but with a higher rate of recurrence in the diclofenac sodium group 12 weeks after treatment completion. 23 …”

Section: Discussionmentioning

confidence: 99%

Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil

Segatto

Dornelles²,

Silveira³

et al. 2013

An. Bras. Dermatol.

View full text Add to dashboard Cite

BACKGROUND Actinic keratosis is a frequent lesion which occurs in sunlight exposed areas. Diclofenac sodium and 5-Fluorouracil are effective, non-invasive and easy-to-apply topical treatment options. OBJECTIVES To assess and compare the effectiveness of 3% diclofenac sodium associated with 2.5% hyaluronic acid and of 5% 5-Fluorouracil for the treatment of actinic keratosis, as well as the patient's degree of satisfaction and tolerability. METHODS28 patients with a clinical diagnosis of actinic keratosis were randomized to receive diclofenac sodium or 5-Fluorouracil and were clinically assessed before and after treatment as well as 8 weeks after the end of treatment. Modified versions of the Investigator and Patient Global Improvement Scores were used. RESULTS The average number of lesions in the diclofenac sodium group before and after treatment was 13.6 and 6.6 (p<0,001), respectively, while it was 17.4 and 3.15 (p<0.001) in the 5-Fluorouracil group. There was a significant reduction in the number of lesions in the 5-Fluorouracil group in relation to the diclofenac sodium group (p<0.001). To the non-blinded physician, there was a higher satisfactory therapeutic response in the 5-Fluorouracil group (p<0.001); to the blinded physician, there was a higher satisfactory response in this same group, although not statistically significant (p=0.09). There was a high degree of satisfaction in both groups (73% in the diclofenac sodium group and 77% in the 5-Fluorouracil group; p=0.827). Regarding adverse effects, the diclofenac sodium group presented a higher degree of satisfaction (93.3% vs 38.4%; p=0.008). Erythema, edema, crusts and itching were significantly higher in the 5-Fluorouracil group. CONCLUSIONWe concluded that 5-Fluorouracil was more effective; however, it showed lower tolerability than diclofenac sodium.

show abstract

Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses

Abstract: Although DFS and IMQ each had considerable efficacy in the treatment of AK, the efficacy of DFS seemed to decrease after cessation of treatment.

Cited by 30 publications

References 19 publications

Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice

Epigallocatechin-3-gallate (EGCG) inhibits imiquimod-induced psoriasis-like inflammation of BALB/c mice

Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer

Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil

Contact Info

Product

Resources

About